<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711187</url>
  </required_header>
  <id_info>
    <org_study_id>AT-03A-002</org_study_id>
    <nct_id>NCT04711187</nct_id>
  </id_info>
  <brief_title>Study of AT-527 in Healthy Subjects (R07496998)</brief_title>
  <official_title>A Phase I Study Assessing the Safety and Pharmacokinetics of Multiple Doses of AT-527 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atea Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportions (active vs. placebo) of subjects experiencing treatment-emergent adverse events.</measure>
    <time_frame>Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of AT-527</measure>
    <time_frame>Days 1 and 5</time_frame>
    <description>Area under the concentration-time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>AT-527 Formulation 1 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Formulation 2 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Formulation 2 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Formulation 1 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Formulation 2 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Formulation 2 Dose 1 Fast/Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AT-527 Formulation 2 Dose 3 Fast/Fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527 Formulation 1</intervention_name>
    <description>AT-527 Formulation 1 (R07496998)</description>
    <arm_group_label>AT-527 Formulation 1 Dose 1</arm_group_label>
    <arm_group_label>AT-527 Formulation 1 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo Comparator</description>
    <arm_group_label>AT-527 Formulation 1 Dose 1</arm_group_label>
    <arm_group_label>AT-527 Formulation 1 Dose 3</arm_group_label>
    <arm_group_label>AT-527 Formulation 2 Dose 2</arm_group_label>
    <arm_group_label>AT-527 Formulation 2 Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527 Formulation 2</intervention_name>
    <description>AT-527 Formulation 2 (R07496998)</description>
    <arm_group_label>AT-527 Formulation 2 Dose 1</arm_group_label>
    <arm_group_label>AT-527 Formulation 2 Dose 1 Fast/Fed</arm_group_label>
    <arm_group_label>AT-527 Formulation 2 Dose 2</arm_group_label>
    <arm_group_label>AT-527 Formulation 2 Dose 3</arm_group_label>
    <arm_group_label>AT-527 Formulation 2 Dose 3 Fast/Fed</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must agree to use two methods of birth control from Screening through 90 days after&#xD;
             administration of the last dose of study drug&#xD;
&#xD;
          -  Females must have a negative pregnancy test at Screening and prior to dosing&#xD;
&#xD;
          -  Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2&#xD;
&#xD;
          -  Willing to comply with the study requirements and to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19&#xD;
&#xD;
          -  Abuse of alcohol or drugs&#xD;
&#xD;
          -  Use of other investigational drugs within 28 days of dosing&#xD;
&#xD;
          -  Other clinically significant medical conditions or laboratory abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>888-481-1607</phone>
    <email>AteaClinicalTrials@ateapharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Atea Study Site</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

